---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-000832"
form_type: "8-K"
ticker: "RKDA"
cik: "0001469443"
company_name: "Arcadia Biosciences, Inc."
filed_at: "2022-02-07T23:59:59+00:00"
generated_at: "2026-06-27T10:36:13.016462+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcadia Biosciences appoints Stan Jacot as CEO; grants inducement option for 316K shares

## Summary
- Stan Jacot named President and CEO effective Feb 2, 2022; previous president of Jane's Dough Foods (6-year tenure with double-digit CAGR).
- Annual base salary $350,000, target bonus 50% of base; inducement stock option for 316,108 shares at $0.91 (vests over four years).
- Kevin Comcowich steps down as interim CEO but remains Chairman of the Board.
- Severance agreement provides 9 months base salary continuation (non-CIC) or 12 months with full equity vesting acceleration after change of control.

## SEC filing metadata
- accession: 0000950170-22-000832
- form_type: 8-K
- ticker: RKDA
- cik: 0001469443
- company_name: Arcadia Biosciences, Inc.
- filed_at: 2022-02-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1469443/000095017022000832/0000950170-22-000832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1469443/000095017022000832/rkda-20220202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-000832
- JSON: https://secwatch.observer/filing/0000950170-22-000832.json
- Plain text: https://secwatch.observer/filing/0000950170-22-000832.txt

## Key facts
- Executive change
  Kevin Comcowich resigned as Interim President and Chief Executive Officer at Arcadia Biosciences, Inc..
  - Action: resigned
  - Role: Interim President and Chief Executive Officer
  source text: In connection with Mr. Jacot’s appointment, Kevin Comcowich resigned as interim president and chief executive officer of the Company, effective February 2, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017022000832/0000950170-22-000832-index.htm
- Executive change
  Stanley Jacot, Jr. was appointed as President and Chief Executive Officer at Arcadia Biosciences, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On February 2, 2022, (the “Effective Date”), Arcadia Biosciences, Inc. (“the Company”) hired Stanley Jacot, Jr. as the new president and chief executive officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017022000832/0000950170-22-000832-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.